Based on these two observations, we raised the hypothesis that mTORi might have different effects on distinct tumor components and compartments, and investigated this possibility in AMLs with different constitutions from a series of TSC, LAM and multiple-AML patients. This evidence concerns the gene TSC1 and acute myeloid leukemia.